[go: up one dir, main page]

AP2000001959A0 - Treatment of generalized anxiety disorder with paroxetine. - Google Patents

Treatment of generalized anxiety disorder with paroxetine.

Info

Publication number
AP2000001959A0
AP2000001959A0 APAP/P/2000/001959A AP2000001959A AP2000001959A0 AP 2000001959 A0 AP2000001959 A0 AP 2000001959A0 AP 2000001959 A AP2000001959 A AP 2000001959A AP 2000001959 A0 AP2000001959 A0 AP 2000001959A0
Authority
AP
ARIPO
Prior art keywords
paroxetine
treatment
anxiety disorder
generalized anxiety
human
Prior art date
Application number
APAP/P/2000/001959A
Inventor
Rocco Zaninelli
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of AP2000001959A0 publication Critical patent/AP2000001959A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A method of treatment of generalised anxiety disorder, which method comprises administering an effective, non-toxic amount of paroxetine or pharmaceutically acceptable salt or solvate thereof, to a human or non-human animal in need thereof.
APAP/P/2000/001959A 1998-04-22 1999-04-22 Treatment of generalized anxiety disorder with paroxetine. AP2000001959A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808479.1A GB9808479D0 (en) 1998-04-22 1998-04-22 Method of treatment
PCT/US1999/008786 WO1999053919A1 (en) 1998-04-22 1999-04-22 Treatment of generalized anxiety disorder with paroxetine

Publications (1)

Publication Number Publication Date
AP2000001959A0 true AP2000001959A0 (en) 2000-12-31

Family

ID=10830715

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2000/001959A AP2000001959A0 (en) 1998-04-22 1999-04-22 Treatment of generalized anxiety disorder with paroxetine.

Country Status (20)

Country Link
EP (1) EP1073437A4 (en)
JP (1) JP2002512189A (en)
KR (1) KR20010034817A (en)
CN (1) CN1298301A (en)
AP (1) AP2000001959A0 (en)
AU (1) AU3864899A (en)
BG (1) BG104939A (en)
BR (1) BR9909791A (en)
CA (1) CA2328896A1 (en)
CZ (1) CZ20003885A3 (en)
EA (1) EA200001088A1 (en)
GB (1) GB9808479D0 (en)
HU (1) HUP0101350A3 (en)
ID (1) ID27546A (en)
IL (1) IL139167A0 (en)
NO (1) NO20005286L (en)
PL (1) PL343494A1 (en)
SK (1) SK15672000A3 (en)
TR (1) TR200003082T2 (en)
WO (1) WO1999053919A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
GB9808479D0 (en) 1998-06-17
BR9909791A (en) 2000-12-26
NO20005286L (en) 2000-12-20
ID27546A (en) 2001-04-12
PL343494A1 (en) 2001-08-27
IL139167A0 (en) 2001-11-25
CN1298301A (en) 2001-06-06
CA2328896A1 (en) 1999-10-28
KR20010034817A (en) 2001-04-25
EP1073437A4 (en) 2003-04-16
EA200001088A1 (en) 2001-04-23
SK15672000A3 (en) 2001-04-09
JP2002512189A (en) 2002-04-23
HUP0101350A2 (en) 2002-05-29
TR200003082T2 (en) 2001-01-22
HUP0101350A3 (en) 2002-06-28
BG104939A (en) 2001-09-28
NO20005286D0 (en) 2000-10-20
EP1073437A1 (en) 2001-02-07
CZ20003885A3 (en) 2001-09-12
WO1999053919A1 (en) 1999-10-28
AU3864899A (en) 1999-11-08

Similar Documents

Publication Publication Date Title
TW200505900A (en) Muscarinic agonists
BR0009776A (en) Treatment method
DK0998287T3 (en) Use of levobupivacaine
BE2012C040I2 (en)
ATE92319T1 (en) PIPERIDE INDIVATE FOR PAIN MANAGEMENT.
AU2003219107A8 (en) Tuberculosis treatment using pleuromutilin derivatives
BG106118A (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
AU2003304410A8 (en) Agents and methods for treatment of disease by oligosaccharide targeting agents
EA200100653A1 (en) THE METHOD OF STRUGGLE AGAINST MEMBERS OF ANIMALS
EA199800866A1 (en) METHOD OF REMOVAL OF PAIN
MY122838A (en) Treating allergic and inflammatory conditions
AP2000001959A0 (en) Treatment of generalized anxiety disorder with paroxetine.
EA200100041A1 (en) METHOD OF TREATMENT
BR9811004A (en) "treatment and prevention of cardiac disorders using selective inhibitors (ssri) of the elevation of the serotonin level"
TR199500984A2 (en) The use of Selegiline in the treatment of epileptic diseases.
EP0904094A4 (en) Treatment of bone disorders with adrenomedullin
EA200100201A1 (en) APPLICATION R - (+) - α- (2, 3-DIMETOXIPHENYL) -1- [2- (4-Fluoro-phenyl) ETHYL] -4-PIPERIDINMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
UA29302A (en) Methods for increasing reproductive function of females of cattle
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
UA31548A (en) The method for prophilaxis and treatment of childs somatic diseases